INTRODUCTION {#s1}
============

MicroRNAs (miRNAs) are a class of small, endogenous, non-coding, single-stranded, highly conserved and tissue-specific RNA molecules which take part in the regulation of target mRNAs expression at the post-transcriptional level \[[@R1], [@R2]\]. By binding to the complementary sequence of the 3' untranslated region of the specific mRNAs, miRNAs could increase or suppress the expression of multiple target genes, including cancer-associated genes, and thus are involved in many physiological and pathological process, such as cell proliferation, cell differentiation, cell apoptosis, carcinogenesis and development and so on \[[@R3], [@R4]\].

As the most common type of genetic variation in the human genome, single nucleotide polymorphisms (SNPs) occurring in miRNA genes have been found to be able to affect miRNA expression and function by interfering the interaction between miRNAs and their corresponding target mRNAs. A large number of studies have demonstrated that SNPs in the miRNA genes are associated with the occurrence of various diseases, such as cancer, so microRNA polymorphisms are considered to be a potentially important mechanism in the acquisition of cancer susceptibility \[[@R5], [@R6]\]. In recent years, some SNPs in miRNAs have been identified as oncogenes of many different types of cancer and found to play an important role in initiation and development of malignancies\[[@R7], [@R8]\].

However, for two common functional microRNA polymorphisms miR-27 rs895819 and miR-423 rs6505162, although many case-control studies involving various cancer types have been performed among different ethnic populations, there is currently no consensus on whether there exists an association between these two microRNA polymorphisms and cancer risk because of inconsistent results published studies reported. In addition, many relevant case-control studies on this theme have been published recently, which will expand the sample size and may have an impact on the evaluation of the association \[[@R9]--[@R13]\]. Therefore, we carried out an updated and systematic meta-analysis including those newly published articles to further assess the correlation of rs895819 and rs6505162 with cancer risk based on all available eligible studies at present.

RESULTS {#s2}
=======

Characteristics of included studies {#s2_1}
-----------------------------------

The selection process of eligible studies is presented in Figure [1](#F1){ref-type="fig"}. A total of 1929 potentially relevant articles were preliminarily identified though a systematic publication search. After excluding duplicate literatures and further carefully reading titles and abstracts of the remaining studies, forty-one articles were performed full-text review for eligibility, among which six articles were excluded for the following reasons: three articles did not have sufficient data; three articles did not conform to HWE. Thus thirty-five articles were considered to meet our inclusion criteria \[[@R9]--[@R43]\]. Among them, seven articles involved not only rs895819 but also rs6505162 \[[@R9], [@R11], [@R14]--[@R15], [@R19], [@R29], [@R36]\]. Moreover, the study by Kontorovich et al. \[[@R36]\] was performed in both breast cancer and ovarian cancer, so we treated the study as two independent investigations. Ultimately, forty-five studies from thirty-five articles were included in quantitative synthesis. The main characteristics of the included studies are listed in Table [1](#T1){ref-type="table"}. Of all the included studies, fifteen focused on breast cancer, eight on esophageal squamous cell carcinoma, six on gastric cancer, five on colorectal cancer, four on lung cancer, two on ovarian cancer, and one each on prostate cancer, gallbladder cancer, cervical cancer, renal cell cancer and hepatocellular carcinoma. In addition, thirty-five studies were carried out among Asians, and eight among Caucasians. A variety of genotyping methods including PCR-RFLP, MassARRAY, Taqman, Sequencing, PCR-LDR, SNaPshot, Allele-specific PCR, ARMS-PCR and HRM were applied in the included studies of this meta-analysis. Moreover, twenty studies were considered as moderate-quality studies (Newcastle-Ottawa Scale scores of these studies were 4-6), and other twenty-five studies were considered as high-quality studies (Newcastle-Ottawa Scale scores of these studies were 7 or above). Genotype distributions of all forty-five studies in the controls were in agreement with Hardy-Weinberg equilibrium (HWE).

![Flow diagram of the selection process of included studies in this meta-analysis](oncotarget-08-46969-g001){#F1}

###### The main characteristics of included studies in the meta-analysis

  First author   Year   Country        Ethnicity   Cancer type   Genotyping methods   Source of controls   Case (n)   Control (n)   HWE   NOS                        
  -------------- ------ -------------- ----------- ------------- -------------------- -------------------- ---------- ------------- ----- ------ ----- ----- ------- ---
  rs895819                                                                                                                                                           
  Jiang          2016   China          Asian       GC            MassARRAY            HB                   480        356           59    537    389   62    0.447   7
  Jiang          2016   China          Asian       CRC           TaqMan               HB                   245        176           87    275    222   65    0.053   7
  Yin            2016   China          Asian       LC            TaqMan               HB                   321        217           37    318    252   38    0.199   7
  Bian           2015   China          Asian       CRC           TaqMan               HB                   199        143           70    205    166   41    0.389   7
  He             2015   China          Asian       BC            MassARRAY            PB                   251        165           34    232    181   37    0.839   7
  Gupta          2015   India          Asian       GBC           TaqMan               PB                   75         81            20    26     24    3     0.399   6
  Nikolic        2015   Serbia         Caucasian   PC            ASPCR                PB                   151        172           30    152    137   19    0.101   6
  Qi             2015   China          Asian       BC            TaqMan               PB                   101        159           61    95     139   56    0.686   7
  Zhang          2015   China          Asian       BC            MassARRAY            PB                   196        150           30    106    70    14    0.605   7
  Yin            2015   China          Asian       LC            TaqMan               HB                   138        103           17    167    125   18    0.391   6
  Cao            2014   China          Asian       CRC           PCR-RFLP             PB                   92         113           49    114    93    31    0.089   7
  Kupcinskas     2014   Countries^a^   Caucasian   CRC           TaqMan               HB                   87         79            25    203    191   34    0.235   4
  Kupcinskas     2014   Countries^b^   Caucasian   GC            TaqMan               HB                   181        144           38    156    164   30    0.151   6
  Song           2014   China          Asian       GC            Sequencing           HB                   105        124           49    131    111   36    0.110   7
  Xiong          2014   China          Asian       CC            PCR-LDR              HB                   48         40            15    223    170   24    0.255   7
  Zhang          2014   China          Asian       ESCC          SNaPshot             PB                   613        414           82    719    466   90    0.226   7
  Ma             2013   China          Asian       BC            MassARRAY            HB                   97         76            16    106    70    14    0.605   6
  Wei            2013   China          Asian       ESCC          MassARRAY            HB                   216        143           20    208    139   30    0.322   6
  Zhang          2013   China          Asian       BC            Sequencing           PB                   152        96            16    137    103   15    0.447   7
  Catucci        2012   Italy          Caucasian   BC            TaqMan               HB                   547        388           90    803    633   157   0.051   5
  Hezova         2012   Czech          Caucasian   CRC           TaqMan               HB                   88         86            23    93     94    25    0.867   6
  Shi            2012   China          Asian       RCC           TaqMan               HB                   334        213           47    288    262   50    0.373   7
  Zhang          2012   China          Asian       BC            PCR-RFLP             PB                   60         144           41    75     109   59    0.123   7
  Zhou           2012   China          Asian       GC            MassARRAY            HB                   166        122           7     214    167   32    0.941   5
  Sun            2010   China          Asian       GC            PCR-RFLP             HB                   115        135           54    145    119   40    0.053   6
  Kontorovich    2010   Israel         Asian       BC            MassARRAY            HB                   98         78            11    101    82    15    0.769   5
  Kontorovich    2010   Israel         Asian       OC            MassARRAY            HB                   43         34            3     101    82    15    0.769   5
  Yang           2010   Germany        Caucasian   BC            Sequencing           PB                   576        486           127   605    660   151   0.142   7
  rs6505162                                                                                                                                                          
  Yin            2016   China          Asian       LC            TaqMan               HB                   389        166           20    368    205   35    0.366   7
  Morales        2016   Chile          Caucasian   BC            TaqMan               HB                   125        229           86    284    385   138   0.700   5
  Jiang          2016   China          Asian       GC            MassARRAY            HB                   593        255           32    656    288   41    0.192   7
  Shen           2016   China          Asian       ESCC          SNaPshot             PB                   920        421           59    1421   680   84    0.814   7
  Zhang          2015   China          Asian       BC            MassARRAY            PB                   231        131           20    110    69    10    0.847   7
  Zhu            2015   China          Asian       ESCC          MassARRAY            PB                   99         122           21    109    140   31    0.159   7
  Yin            2015   China          Asian       LC            TaqMan               HB                   177        74            7     190    106   14    0.872   6
  He             2015   China          Asian       BC            MassARRAY            PB                   292        142           16    299    129   22    0.103   7
  Ma             2014   China          Asian       HCC           MassARRAY            HB                   652        297           42    643    313   30    0.273   7
  Ma             2013   China          Asian       BC            MassARRAY            HB                   127        57            8     110    69    10    0.847   6
  Umar           2013   India          Asian       ESCC          ARMS-PCR             HB                   90         132           67    96     143   70    0.233   7
  Yin            2013   China          Asian       ESCC          PCR-LDR              HB                   374        197           29    425    207   19    0.299   7
  Wang           2013   Countries^c^   Black       ESCC          TaqMan               PB                   207        128           16    376    184   12    0.052   6
  Wang           2013   Countries^c^   Mixed       ESCC          TaqMan               PB                   89         84            14    198    188   34    0.249   5
  Smith          2012   Australia      Caucasian   BC            HRM                  HB                   60         95            24    52     80    42    0.307   7
  Kontorovich    2010   Israel         Caucasian   BC            iPLEX                PB                   68         88            34    55     102   49    0.899   5
  Kontorovich    2010   Israel         Caucasian   OC            iPLEX                PB                   31         26            22    55     102   49    0.899   5

A: the major allele; B: the minor allele; ASPCR: allele-specific PCR; GC: gastric cancer; CRC: colorectal cancer; LC: lung cancer; BC: breast cancer; GBC: gallbladder cancer; PC: prostate cancer; CC: cervical cancer; ESCC: esophageal squamous cell carcinoma; RCC: renal cell cancer; OC: ovarian cancer; HCC: hepatocellular carcinoma; PB: population based; HB: hospital based; a: Lithuania and Latvia; b: German, Lithuanian and Latvian; c: South Africa.

Meta-analysis results {#s2_2}
---------------------

The main meta-analysis results of the correlation between rs895819 A \> G and cancer susceptibility are listed in Table [2](#T2){ref-type="table"}. In the overall analysis, we couldn\'t detect an association of the rs895819 polymorphism with cancer risk in all five genetic models. However, when analysis was stratified by ethnicity, a decreased cancer risk was observed in the Caucasian population (AG vs. AA: OR = 0.87, 95% CI = 0.79-0.96; GG+AG vs. AA: OR = 0.89, 95% CI = 0.81-0.98), while no significant correlation was found among Asians in all the genetic models (Table [2](#T2){ref-type="table"}) (Figure [2](#F2){ref-type="fig"}). Moreover, the stratified analysis by cancer type revealed that rs895819 was associated with an increased risk of colorectal cancer (G vs. A: OR = 1.19, 95% CI = 1.08-1.32; GG vs. AA: OR = 1.58, 95% CI = 1.28-1.96; GG vs. AG+AA: OR = 1.58, 95% CI = 1.29-1.93), and a decreased risk of breast cancer (G vs. A: OR = 0.93, 95% CI = 0.87-0.99; GG+AG vs. AA: OR = 0.91, 95% CI = 0.83-0.99) (Table [2](#T2){ref-type="table"}) (Figure [3](#F3){ref-type="fig"}). Nevertheless, we didn\'t find an association of the rs895819 polymorphism with risks of lung cancer, gastric cancer, prostate cancer, gallbladder cancer, cervical cancer, renal cell cancer, ovarian cancer and esophageal squamous cell carcinoma. We also performed the subgroup analysis by source of controls and the result indicated that there was no association between rs895819 and cancer risk in either population-based subgroup or hospital-based subgroup.

###### Meta-analysis results of the association between rs895819 and cancer risk

  Variables            N^a^   G vs. A               GG vs. AA   AG vs. AA             GG+AG vs. AA   GG vs.AG+AA                                                                     
  -------------------- ------ --------------------- ----------- --------------------- -------------- --------------------- ------ --------------------- ------ --------------------- ------
  Overall              28     1.03 (0.97,1.10)^b^   56.4        1.12 (0.97,1.29)^b^   52.2           0.99 (0.91,1.06)^b^   42.6   1.01 (0.94,1.09)^b^   49.7   1.11 (0.97,1.26)^b^   49.6
  Ethnicity                                                                                                                                                                          
  Asians               22     1.05 (0.97,1.13)^b^   55.9        1.13 (0.95,1.34)^b^   54.2           1.02 (0.93,1.11)^b^   36.6   1.04 (0.95,1.13)^b^   44.9   1.10 (0.93,1.30)^b^   54.9
  Caucasians           6      0.94 (0.88,1.01)      48.7        0.98 (0.83,1.15)      36.8           0.87 (0.79,0.96)      43.0   0.89 (0.81,0.98)      49.0   1.05 (0.90,1.22)      23.1
  Cancer type                                                                                                                                                                        
  BC                   9      0.93 (0.87,0.99)      0.0         0.90 (0.78,1.04)      0.0            0.97 (0.84,1.11)^b^   50.3   0.91 (0.83,0.99)      33.7   0.92 (0.80,1.05)      0.0
  CRC                  5      1.19 (1.08,1.32)      9.9         1.58 (1.28,1.96)      0.0            0.98 (0.85,1.14)      29.3   1.11 (0.97,1.27)      23.0   1.58 (1.29,1.93)      0.0
  LC                   2      0.95 (0.82,1.11)      0.0         1.02 (0.69,1.51)      0.0            0.90 (0.74,1.09)      0.0    0.91 (0.76,1.10)      0.0    1.07 (0.73,1.57)      0.0
  GC                   5      1.06 (0.87,1.29)^b^   75.7        1.08 (0.68,1.70)^b^   74.7           1.06 (0.86,1.31)^b^   60.8   1.08 (0.85,1.36)^b^   70.9   1.05 (0.71,1.56)^b^   68.6
  ESCC                 2      1.00 (0.89,1.12)      25.4        0.95 (0.72,1.26)      54.1           1.03 (0.89,1.19)      0.0    1.02 (0.88,1.17)      0.0    0.94 (0.72,1.24)      52.4
  Others               5      1.09 (0.84,1.41)^b^   74.3        1.35 (0.73,2.49)^b^   69.0           0.99 (0.75,1.31)^b^   59.5   1.05 (0.77,1.43)^b^   69.4   1.35 (0.80,2.28)^b^   60.5
  Source of controls                                                                                                                                                                 
  PB                   10     1.04 (0.94,1.15)^b^   55.9        1.05 (0.91,1.21)      22.2           1.06 (0.90,1.24)^b^   63.7   1.07 (0.92,1.24)^b^   63.8   1.03 (0.90,1.18)      15.2
  HB                   18     1.03 (0.94,1.11)^b^   59.0        1.12 (0.91,1.37)^b^   61.7           0.94 (0.88,1.01)      21.4   0.99 (0.90,1.08)^b^   40.5   1.14 (0.94,1.37)^b^   58.9

a: number of studies; b: calculating based on random-effects model; BC: breast cancer; CRC: colorectal cancer; LC: lung cancer; GC: gastric cancer; ESCC: esophageal squamous cell carcinoma.

![Forest plot of the association between rs895819 and cancer risk in subgroup analysis by ethnicity under heterozygote model](oncotarget-08-46969-g002){#F2}

![Forest plot of the association between rs895819 and cancer risk in subgroup analysis by cancer type under allele contrast model](oncotarget-08-46969-g003){#F3}

For rs6505162 C \> A, no significant risk association was observed in the overall analysis. Similarly, when grouped by ethnicity, we couldn\'t detect a correlation of the rs6505162 polymorphism with cancer risk in either Caucasians or Asians. However, after subgroup analysis by cancer type, the rs6505162 polymorphism was found to be associated with a decreased risk of lung cancer in all five genetic models (A vs. C: OR = 0.75, 95% CI = 0.63-0.88; AA vs. CC: OR = 0.54, 95% CI = 0.33-0.88; AC vs. CC: OR = 0.76, 95% CI = 0.62-0.93; AA+AC vs. CC: OR = 0.73, 95% CI = 0.60-0.89; AA vs. AC+CC: OR = 0.59, 95% CI = 0.37-0.95) (Table [3](#T3){ref-type="table"}) (Figure [4](#F4){ref-type="fig"}). Besides, subgroup analysis by source of controls revealed that there was no correlation between rs6505162 and cancer susceptibility in either population-based subgroup or hospital-based subgroup.

###### Meta-analysis results of the association between rs6505162 and cancer risk

  Variables            N^a^   A vs. C               AA vs. CC   AC vs. CC             AA+AC vs. CC   AA vs. AC+CC                                                                    
  -------------------- ------ --------------------- ----------- --------------------- -------------- --------------------- ------ --------------------- ------ --------------------- ------
  Overall              17     0.96 (0.88,1.04)^b^   56.1        0.93 (0.77,1.14)^b^   50.7           0.96 (0.87,1.05)^b^   40.2   0.95 (0.86,1.05)^b^   50.6   0.96 (0.81,1.14)^b^   40.6
  Ethnicity                                                                                                                                                                          
  Asians               11     0.96 (0.90,1.02)      35.3        0.96 (0.82,1.13)      27.7           0.94 (0.87,1.01)      0.0    0.94 (0.88,1.01)      16.9   0.98 (0.84,1.15)      19.2
  Caucasians           4      0.88 (0.66,1.17)^b^   78.3        0.7 7(0.44,1.35)^b^   77.0           0.85 (0.54,1.36)^b^   78.0   0.84 (0.54,1.30)^b^   79.3   0.86 (0.56,1.31)^b^   69.7
  Cancer type                                                                                                                                                                        
  LC                   2      0.75 (0.63,0.88)      0.0         0.54 (0.33,0.88)      0.0            0.76 (0.62,0.93)      0.0    0.73 (0.60,0.89)      0.0    0.59 (0.37,0.95)      0.0
  BC                   6      0.91 (0.75,1.09)^b^   67.3        0.79 (0.52,1.19)^b^   63.2           1.03 (0.90,1.19)      51.7   0.93 (0.74,1.18)^b^   62.5   0.87 (0.71,1.07)^b^   47.1
  ESCC                 6      1.04 (0.96,1.13)      33.9        1.13 (0.92,1.39)      38.7           1.02 (0.92,1.13)      0.0    1.04 (0.94,1.14)      5.6    1.12 (0.92,1.37)      30.8
  Others               3      0.98 (0.88,1.09)      0.0         1.02 (0.76,1.38)      20.6           0.92 (0.81,1.06)      63.7   0.94 (0.83,1.07)      43.9   1.14 (0.85,1.52)      5.3
  Source of controls                                                                                                                                                                 
  PB                   8      0.98 (0.91,1.06)      40.0        0.93 (0.76,1.13)      36.2           0.97 (0.88,1.08)      44.1   0.98 (0.89,1.08)      45.9   0.98 (0.81,1.19)      22.0
  HB                   9      0.94 (0.83,1.06)^b^   67.7        0.93 (0.69,1.26)^b^   61.9           0.96 (0.88,1.05)      43.7   0.94 (0.82,1.09)^b^   58.7   0.9 3(0.72,1.21)^b^   55.5

a: number of studies; b: calculating based on random-effects model; LC: lung cancer; BC: breast cancer; ESCC: esophageal squamous cell carcinoma.

![Forest plot of the association between rs6505162 and cancer risk in subgroup analysis by cancer type under homozygote model](oncotarget-08-46969-g004){#F4}

Sensitivity analysis {#s2_3}
--------------------

In order to evaluate the stability of our results, we performed the sensitivity analysis to assess the effect of each individual study on the pooled ORs. After sequentially excluding each eligible studies, the corresponding ORs were not substantially changed, showing that the results of this meta-analysis are statistically stable.

Heterogeneity analysis {#s2_4}
----------------------

Q test and I^2^ test were used to assess the heterogeneity among studies. When obvious between-study heterogeneity (*P* value of Q test was less than 0.1 or I^2^ value was greater than 75%) was observed in the overall pooled analysis or subgroup analysis, the random-effects model would be applied because it could generate wider confidence intervals. Otherwise, we would select fixed-effects model to conduct related data analysis.

Publication bias {#s2_5}
----------------

The Begg\'s funnel plot and Egger\'s test were performed to examine the publication bias in this meta-analysis. For rs895819, no publication bias was found in allele contrast model, homozygote model and recessive model, and the shape of the funnel plots appeared to relatively symmetrical (Figure [5](#F5){ref-type="fig"}). However, there was evidence of significant publication bias in the other two genetic models (*P* values of Begg\'s test and Egger\'s test were less than 0.05). Similarly, we could not observe a publication bias for the rs6505162 polymorphism in three of five comparison models including homozygote model, heterozygote model and recessive model. Interestingly, for both allele contrast model and recessive model, *P* values of Egger\'s test in these two genetic models were all \> 0.05, while that of Begg\'s test were all \< 0.05, which might be due to small sample size and limited number of studies included in this meta-analysis. Therefore, there might exist publication bias in our study.

![Begg\'s funnel plot of rs895819 in recessive model](oncotarget-08-46969-g005){#F5}

DISCUSSION {#s3}
==========

In the current meta-analysis, a total of forty-five eligible case-control studies from thirty-five articles were included and their pooled results were used to assess the association of microRNA polymorphisms including miR-27 rs895819 and miR-423 rs6505162 with cancer susceptibility. We found that the rs895819 polymorphism was associated with a decreased cancer risk in Caucasians and breast cancer, while a significantly increased risk for developing cancer could be detected in colorectal cancer under allele contrast model, homozygote model and recessive model. In addition, for the rs6505162 polymorphism, a significantly decreased risk for cancer could be observed in lung cancer when data were stratified by cancer type.

As an important member of the microRNAs family, miR-27 is located in the intergenic region of chromosome 19 and is involved in the occurrence, invasion and metastasis of many types of cancer by acting as an oncogene. The miR-27 displays its oncogenic property through regulating the expression of target genes including FOXO1 \[[@R44]\], BTG2 \[[@R45]\], PHB \[[@R46]\] and other cancer-related genes \[[@R47]\]. Studies have reported that genetic mutations in miRNA precursors (pre-miRNA) can alter miRNA expression levels and their binding with several nuclear factors during miRNA processing \[[@R48]\]. Consequently, rs895819, an A to G nucleotide substitution occurring in pre-miR-27a, can down-regulate miR-27 by influencing its expression and/or maturation, and thus may lead to a reduction of individual susceptibility to cancer. Our results support this inference. In our study, we found that rs895819 could decrease the risk of breast cancer in allele contrast model and dominant model.

In addition to being able to function as an oncogene, many studies have demonstrated that miR-27a can also play an essential role as a tumor-suppressor gene in the development and progression of various cancer. For example, Bao and colleagues found that miR-27a could act as a tumor suppressor for colorectal cancer through inhibiting colon cancer cell proliferation and migration, and inducing colon cancer cell apoptosis \[[@R49]\]. As described in the previous paragraph, the rs895819 polymorphism can down-regulate the expression of miR-27, which will affect the tumor suppressor function of miR-27, so rs895819 may be able to promote the occurrence and development of colorectal cancer by attenuating miR-27\'s tumor suppressive effect. Therefore, rs895819 may be a risk factor for colorectal cancer, which is consistent with the results of our study. In our meta-analysis, the rs895819 polymorphism was found to be associated with an increased risk of colorectal cancer in allele contrast model, homozygote model and recessive model. In addition, three latest publications reported similar results \[[@R50]--[@R52]\], which will make our conclusions more credible. Moreover, when analysis was stratified by ethnicity, a decreased cancer risk could be detected among Caucasians, indicating that the distinction in genetic backgrounds among different ethnic groups might have an impact on cancer susceptibility, which was in accordance with the results of five previously published studies \[[@R52]--[@R56]\] and further demonstrated the reliability of our results.

For rs6505162, our results showed that there was no association between rs6505162 and cancer risk in the overall pooled analysis. When grouped by race, similar results could still be observed among both Asian populations and Caucasian populations. However, in the subgroup analysis by cancer type, a significantly decreased cancer risk was found in lung cancer, demonstrating that rs6505162 polymorphism might be a protective factor for lung cancer. But considering that only two studies were included in the analysis, we should treat the result with caution. Our results were different from a previously published study by Hu et al. \[[@R57]\], which included eight studies and found that rs6505162 was a risk factor for cancer, especially for bladder cancer. This discrepancy may be due to differences in sample sizes and ethnic groups: compared with his study, our study included seventeen eligible studies, which would expand the sample size more than twice and thus get a more credible assessment of the association.

However, some limitations of this meta-analysis should be addressed. Firstly, several important individual information such as age, sex, environmental factor was not available for most of studies included in our meta-analysis, so we couldn\'t carry out a more detailed analysis grouped by other non-genetic risk factors of cancer. Secondly, there existed a moderate degree of heterogeneity among the included studies, however, when analysis stratified by cancer type or race, between-study heterogeneity obviously reduced, demonstrating that heterogeneity might partly stem from differences in cancer types and ethnicities. Thirdly, many kinds of genotyping methods were applied in the included studies of our meta-analysis, which might have a potential impact on the results. Fourthly, publication bias existed for both rs895819 and rs6505162 because only studies collected into PubMed, EMBASE and Web of Science databases and published in English were selected into our meta-analysis. Those literatures not collected into these three databases or published not in English were not included in our analysis, which might contain other eligible studies and thus cause publication bias. Therefore, in view of these limitations, we should cautiously treat the results of our study.

In conclusion, our results indicate that miR-27 rs895819 is a protective factor for developing cancer in Caucasian populations and could increase colorectal cancer risk but decrease breast cancer risk. For miR-423 rs6505162, it could decrease the risk of lung cancer. More multi-center large-scale case-control studies with larger sample sizes are needed to confirm our results.

MATERIALS AND METHODS {#s4}
=====================

Literature and search strategy {#s4_1}
------------------------------

A comprehensive literature search of all eligible studies published before October 21, 2016 was conducted in PubMed, EMBASE and Web of Science electronic databases. During our searching process, the following retrieval items were applied: ("microRNA 27" OR "microRNA-27" OR "miR-27" OR "rs895819" OR "microRNA 423" OR "microRNA-423" OR "miR-423" OR "rs6505162") AND ("polymorphism" OR "SNP" OR "variation" OR "locus" OR "mutation") AND ("cancer" OR "tumor" OR "malignancy" OR "carcinoma" OR "neoplasm").

Criterion for study selection {#s4_2}
-----------------------------

All eligible studies included in this meta-analysis must meet the following criteria: (1) evaluating the association of rs895819/rs6505162 with cancer risk; (2) case-control design; (3) providing sufficient genotyping data for estimating odds ratios (ORs) and 95% confidence intervals (CIs); (4) genotype frequencies of subjects in controls were in accordance with Hard-Weinberg equilibrium (HWE); (5) all cancer cases were confirmed by pathology. The exclusion criteria were as follows: (1) not case-control studies; (2) case reports, comments or review articles; (3) duplicate articles; (4) the control groups did not conform to HWE; (5) lack of enough genotyping data.

Data extraction and quality assessment {#s4_3}
--------------------------------------

Two independent investigators carefully collected the following information from each study included in this meta-analysis: first author, year, country, ethnicity, cancer type, genotyping method, source of controls, number of cases and controls, genotype distribution of cases and controls, and *P* value of Hardy-Weinberg equilibrium (HWE) in controls. Any inconsistency was resolved through discussion until a consensus was reached. Moreover, we also evaluated the methodological quality of included studies based on Newcastle-Ottawa Scale (NOS), which scored studies according to three aspects: selection, comparability, and exposure. Therefore, all studies could be divided into three categories: "low quality" studies (score 0-3); "moderate quality" studies (score 4-6); "high quality" studies (score 7-9).

Statistical method {#s4_4}
------------------

The association of rs895819 and rs6505162 with cancer susceptibility was estimated by pooled odds ratios (ORs) and 95% confidence intervals (CIs) under five different genetic models including allele contrast model, homozygote model, heterozygote model, dominant model and recessive model. Both Q-statistical test and I^2^ test were applied to assess the between-study heterogeneity in this meta-analysis. If there was significant heterogeneity among included studies (*P* value of Q statistic was \< 0.1 or I^2^ value was \> 75%), ORs with corresponding 95% CIs would be calculated using the random-effects model; otherwise, the fixed-effects model would be selected. The subgroup analysis was undertaken according to ethnicity, cancer type (investigations consisting of only one study were merged into the "others" group) and source of controls. We conducted sensitivity analysis by sequentially omitting a single study each time to assess the influence of individual study on the pooled ORs. Moreover, we employed Begg\'s funnel plot and Egger\'s test (*P* \< 0.05 was considered significant) to assess whether there existed publication bias. Besides, chi-square test was applied to calculate *P* value of Hardy-Weinberg equilibrium (HWE) in controls. All data analyses performed in the present analysis were carried out using STATA 12.0 software (StataCorp LP, College Station, TX, USA). All statistical tests were two sided, and *P* \< 0.05 indicated statistical significance.
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